The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease

References

• Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–1590.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–184.
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med. 1998;339(15):1044–1053.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–474.
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Relat Disord. 1998;4(2):59–60.
   PubMedGoogle Scholar
• Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord. 2007;22(10):1379–1389; quiz 1523.
   Web of Science ®Google Scholar
• Nutt JG. Motor fluctuations and dyskinesia in Parkinson’s disease. Parkinsonism Relat Disord. 2001;8(2):101–108.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord. 2004;19(9):997–1005.
   PubMed Web of Science ®Google Scholar
• Rascol O, Payoux P, Ory F, et al. Limitations of current Parkinson’s disease therapy. Ann Neurol. 2003;53(Suppl 3):S3–S12.
   PubMed Web of Science ®Google Scholar
• Antonini A, Barone P. Dopamine agonist-based strategies in the treatment of Parkinson’s disease. Neurol Sci. 2008;29(Suppl 5):S371–S374.
   Google Scholar
• Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs. 2010;24(11):941–968.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rascol O. Safety of rasagiline for the treatment of Parkinson’s disease. Expert Opin Drug Saf. 2011;10(4):633–643.
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S2–S41.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361(13):1268–1278.
   PubMed Web of Science ®Google Scholar
• Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67(7 Suppl 2):S18–S23.
   PubMed Web of Science ®Google Scholar
• Dezsi L, Vecsei L. Safinamide for the treatment of Parkinson’s disease. Expert Opin Investig Drugs. 2014;23(5):729–742.
   PubMed Web of Science ®Google Scholar
• Kandadai RM, Jabeen SA, Kanikannan MA, et al. Safinamide for the treatment of Parkinson’s disease. Expert Rev Clin Pharmacol. 2014;7(6):747–759.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Safinamide: first global approval. Drugs. 2015;75(6):705–711.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of product characteristics: Xadago (safinamide 50 mg coated tablets). London: European Medicines Agency; 2014.
   Google Scholar
• Marzo A, Dal Bo L, Monti NC, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004;50(1):77–85.
   PubMed Web of Science ®Google Scholar
• Foley P, Gerlach M, Youdim MB, et al. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?. Parkinsonism Relat Disord. 2000;6(1):25–47.
   PubMed Web of Science ®Google Scholar
• Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132(2):500–506.
   PubMed Web of Science ®Google Scholar
• Pevarello P, Traquandi G, Bonsignori A, et al. Synthesis and preliminary biological evaluation of new alpha-amino amide anticonvulsants incorporating a dextromethorphan moiety. Bioorg Med Chem Lett. 1999;9(13):1783–1788.
   PubMed Web of Science ®Google Scholar
• Salvati P, Maj R, Caccia C, et al. Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther. 1999;288(3):1151–1159.
   PubMed Web of Science ®Google Scholar
• Fariello RG, Maj R, Marrari P, et al. Acute behavioral and EEG effects of NW-1015 on electrically-induced afterdischarge in conscious monkeys. Epilepsy Res. 2000;39(1):37–46.
   PubMed Web of Science ®Google Scholar
• Maj R, Fariello RG, Ukmar G, et al. PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. Eur J Pharmacol. 1998;359(1):27–32.
   PubMed Web of Science ®Google Scholar
• Fariello RG. Safinamide. Neurotherapeutics. 2007;4(1):110–116.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63(4):746–748.
   PubMed Web of Science ®Google Scholar
• Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson’s disease. Expert Opin Investig Drugs. 2008;17(7):1115–1125.
   PubMed Web of Science ®Google Scholar
• Leuratti C, Sardina M, Ventura P, et al. Disposition and metabolism of safinamide, a novel drug for Parkinson’s disease, in healthy male volunteers. Pharmacology. 2013;92(3–4):207–216.
   PubMed Web of Science ®Google Scholar
• Gregoire L, Jourdain VA, Townsend M, et al. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord. 2013;19(5):508–514.
   PubMed Web of Science ®Google Scholar
• Podurgiel S, Collins-Praino LE, Yohn S, et al. Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. Pharmacol Biochem Behav. 2013;105:105–111.
   PubMed Web of Science ®Google Scholar
• Sadeghian M, Mullali G, Pocock JM, et al. Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson’s disease. Neuropathol Appl Neurobiol. 2015. doi:10.1111/nan.12263.
   PubMedGoogle Scholar
• Zhu J, Chu CT. Mitochondrial dysfunction in Parkinson’s disease. J Alzheimers Dis. 2010;20(Suppl 2):S325–S334.
   Google Scholar
• Perez-Lloret S, Sampaio C, Rascol O. Disease-modifying strategies in Parkinson’s disease. In: Jankovik J, Tolosa E, editors. Parkinson’s disease and movement disorders. Philadelphia (PA): Wolters Kluwer; 2015.
   Google Scholar
• Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology. 2006;67(7 Suppl 2):S24–S29.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Borgohain R, Onofrj M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Mov Disord. 2012;27(1):106–112.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Stocchi F, Borgohain R, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease. Eur J Neurol. 2013;20(2):271–280.
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014;29(2):229–237.
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014;29(10):1273–1280.
   PubMed Web of Science ®Google Scholar
• Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The unified Parkinson’s disease rating scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738–750.
   PubMed Web of Science ®Google Scholar
• Barone P, Fernandez HH, Ferreira J, et al. Safinamide add‑on to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multi-center trial in early idiopathic Parkinson’s disease (PD) patients (MOTION). Neurology. 2013;80(Meeting Abstracts):P01.061.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Fox S, Hauser RA, et al. Safinamide add‑on to L-dopa: a randomized, placebo-controlled, 24-week global trial in patients with Parkinson’s disease (PD) and motor fluctuations (SETTLE). Neurology. 2013;80(Meeting Abstracts):P01.062.
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351(24):2498–2508.
   PubMed Web of Science ®Google Scholar
• Rascol O. Defining a minimal clinically relevant difference for the unified Parkinson’s rating scale: an important but still unmet need. Mov Disord. 2006;21(8):1059–1061.
   PubMed Web of Science ®Google Scholar
• Schrag A, Sampaio C, Counsell N, et al. Minimal clinically important change on the unified Parkinson’s disease rating scale. Mov Disord. 2006;21(8):1200–1207.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Deckers F, Lehert P. Parkinson’s disease home diary: further validation and implications for clinical trials. Mov Disord. 2004;19(12):1409–1413.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Ferla RL, Bonizzoni E, et al. Long-term effects of safinamide on dyskinesia in mid- to late-stage Parkinson’s disease: a post-hoc analysis. J Parkinsons Dis. 2015;5(3):475–481.
   PubMedGoogle Scholar
• Hauser RA, Gordon MF, Mizuno Y, et al. Minimal clinically important difference in Parkinson’s disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014;2014:467131.
   PubMed Web of Science ®Google Scholar
• Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010;(7):CD007166.
   Google Scholar
• Barone P, Cattaneo C, Bonizzoni E, et al. Safinamide significantly reduces pain treatments when given as add-on therapy to levodopa in patients with Parkinson’s disease and fluctuations [abstract]. Mov Disord. 2015;30(Suppl. 1):S150.
   Google Scholar
• Borgohain R, Mehta D, Bajenaru OA, et al. Effect of safinamide on depressive symptoms in patients with mid-late stage Parkinson’s disease [abstract]. Mov Disord. 2010;25(Suppl. 2):S291.
   Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. Impact of pharmacotherapy on quality of life in patients with Parkinson’s disease. CNS Drugs. 2015;29(5):397–413.
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947–954.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(6):261–265.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–595.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Caccia C, Marzo A, et al. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin Neuropharmacol. 2003;26(4):213–217.
   PubMed Web of Science ®Google Scholar
• Marquet A, Kupas K, Johne A, et al. The effect of safinamide, a novel drug for Parkinson’s disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clin Pharmacol Ther. 2012;92(4):450–457.
   PubMed Web of Science ®Google Scholar
• Olanow CW. A rational approach to the treatment of early Parkinson’s disease. Parkinsonism Relat Disord. 1999;5(4):217–220.
   PubMed Web of Science ®Google Scholar
• Olanow WC, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28(8):1064–1071.
   PubMed Web of Science ®Google Scholar
• Schapira AHV. Treatment options in the modern management of Parkinson disease. Arch Neurol. 2007;64(8):1083–1088.
   PubMedGoogle Scholar
• Schapira AH, Olanow CW. Drug selection and timing of initiation of treatment in early Parkinson’s disease. Ann Neurol. 2008;64(Suppl 2):S47–S55.
   Google Scholar
• Negre-Pages L, Regragui W, Bouhassira D, et al. Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord. 2008;23(10):1361–1369.
   PubMed Web of Science ®Google Scholar
• Reyes D, Kurako K, Galvez-Jimenez N. Rasagiline induced hypersexuality in Parkinson’s disease. J Clin Neurosci. 2014;21(3):507–508.
   PubMed Web of Science ®Google Scholar